For SMEs and biotechs expanding across Europe, scaling pharmacovigilance (PV) isn’t about adding people; it’s about building a lean, compliant engine that can absorb more products and countries without breaking under Good Pharmacovigilance Practices (GVP) scrutiny. That depends on how well three fundamentals are managed: data, systems, and people.
Data: a controlled and audit-ready foundation
If PV data lives across spreadsheets, inboxes, and local tools, scale only amplifies noise and risk. The goal is to maintain a clean, structured, and retraceable data layer across Individual Case Safety Report (ICSR) intake, processing, submissions, and signal decisions. Consistent coding, duplicate control, and harmonized literature capture feed a single safety source that the QPPV can oversee. In the EU context, this directly supports the documented PV system and oversight duties in GVP.
Systems: built to support work, not create work
Technology should remove friction and compliance risk, not add more of it. Interoperable validated components (safety database, literature tool, QMS/eDMS, analytics) avoid re-entry and reconstruction work. Connectivity to EudraVigilance, aligned templates, and audit trails enable full traceability. One coherent architecture scales far better than a patchwork of country-level tools.
People: roles, governance, and controlled execution
Even strong tools fail without clear ownership. Define responsibilities across HQ, affiliates, and vendors; ensure QPPV visibility is real (not nominal) through dashboards, cadences, and escalation rules. Decide where detection, triage, and signal assessment sit and document decision-making so it stands up to inspection. Capability matters, but governance and clarity are what make capability usable at scale.
Making it work in real life, without overspending
For lean teams, success comes from designing around non-negotiables (EU timelines, data quality, inspection readiness) and then scaling with discipline, not by accident.
Standardize the core (case workflow, coding, submissions, signal mechanics) and localize only what national rules force, not more. Treat literature and duplicates as engineered workflows, not side-tasks.
Within that logic, specialized partners can enable scale without losing control. They bring surge capacity, niche expertise (e.g. language-specific literature, statistics for signals), and ready-made GVP-aligned workflows. The key is to integrate them under your QMS with SLAs/KPIs and a single shared oversight layer, so external execution does not dilute accountability.
Conclusion
Whether a company runs a centralized, hybrid, or decentralized model, the realities of scaling PV in Europe are the same: control of data, interoperability of systems, and governed people/process execution are what keep the system compliant and scalable. Operating models differ; the conditions for making them work do not.
Want to dive deeper? Register for our webinar to get practical examples, ready-to-use templates, and insights directly applicable to your PV setup. We’ll walk through real-world decision paths for SMEs and biotechs.
Need support? Contact QbD Group today.
About the Author
Former QPPV · Division Head Vigilance & Country Manager Spain
Almudena leads pharmacovigilance strategy and operations at QbD Group as Division Head of Vigilance and Country Manager for Spain, helping pharma and biotech companies build robust drug safety systems.
Strengthen Your Pharmacovigilance System
QbD Group offers a full range of pharmacovigilance services to ensure your products meet compliance standards while safeguarding patient safety.
Read moreSubscribe to the latest updates in life science
Expert perspectives delivered to your inbox — pick your interests.
No spam, ever. Unsubscribe anytime.
